Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nektar Therapeutics

0.7520
-0.0281-3.60%
Post-market: 0.7500-0.0020-0.27%19:46 EDT
Volume:1.40M
Turnover:1.06M
Market Cap:139.95M
PE:-1.30
High:0.8000
Open:0.7888
Low:0.7400
Close:0.7801
Loading ...

Nektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial Markets

PR Newswire
·
02 May

Will Nektar Therapeutics (NKTR) Report Negative Q1 Earnings? What You Should Know

Zacks
·
01 May

Jefferies Upgrades Nektar Therapeutics to Buy, Doubles Price Target to $2.00

GuruFocus.com
·
12 Apr

Nektar Therapeutics Shares Rise After Upgrade From Jefferies

MT Newswires Live
·
12 Apr

Nektar Therapeutics Raised to Buy From Hold by Jefferies

Dow Jones
·
11 Apr

Jefferies Upgrades Nektar Therapeutics to Buy From Hold, Adjusts Price Target to $2 From $1

MT Newswires Live
·
11 Apr

Nektar upgraded to Buy from Hold at Jefferies

TIPRANKS
·
11 Apr

Little Excitement Around Nektar Therapeutics' (NASDAQ:NKTR) Revenues As Shares Take 29% Pounding

Simply Wall St.
·
04 Apr

BRIEF-Nektar Therapeutics - Enters Equity Distribution Agreement Up To $75 Million - SEC Filing

Reuters
·
29 Mar

Nektar Therapeutics - Enters Equity Distribution Agreement up to $75 Million - SEC Filing

THOMSON REUTERS
·
29 Mar

Nektar Therapeutics - to Pay 3.0% Commission Fee to Piper and Btig - SEC Filing

THOMSON REUTERS
·
29 Mar

Nektar Therapeutics Files $300 Million Mixed Shelf

MT Newswires Live
·
29 Mar

Nektar files $300M mixed securities shelf

TIPRANKS
·
29 Mar

BRIEF-Nektar Therapeutics Files For Mixed Shelf Offering Of Up To $300 Million - SEC Filing

Reuters
·
29 Mar

Nektar Therapeutics: Files for Mixed Shelf Offering of up to $300 Mln - SEC Filing

THOMSON REUTERS
·
29 Mar

Nektar Therapeutics (NKTR): Among Stocks Wall Street Is Calling Bullish Amid Market Turmoil

Insider Monkey
·
23 Mar

Nektar Therapeutics Shares Rise After Upgrade From Oppenheimer

MT Newswires Live
·
15 Mar

Nektar Therapeutics Raised to Outperform From Perform by Oppenheimer

Dow Jones
·
14 Mar

Nektar Therapeutics : Oppenheimer Raises to Outperform From Perform

THOMSON REUTERS
·
14 Mar

Nektar Therapeutics (NKTR) Q4 Earnings Miss Estimates (Revised)

Zacks
·
14 Mar